We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Syndax Pharmaceuticals Inc (SNDX) USD0.0001

Sell:$21.22 Buy:$21.27 Change: $0.24 (1.15%)
NASDAQ:1.41%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$21.22
Buy:$21.27
Change: $0.24 (1.15%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$21.22
Buy:$21.27
Change: $0.24 (1.15%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. It is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant A. It is also exploring the use of revumenib as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.

Contact details

Address:
35 Gatehouse Drive, Building D, Floor 3
WALTHAM
02451
United States
Telephone:
+1 (781) 4191400
Website:
https://syndax.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SNDX
ISIN:
US87164F1057
Market cap:
$1.77 billion
Shares in issue:
84.98 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Neil Gallagher
    President, Head of Research and Development
  • Michael Metzger
    Chief Executive Officer, Director
  • Keith Goldan
    Chief Financial Officer, Principal Accounting Officer, Treasurer
  • Peter Ordentlich
    Chief Scientific Officer
  • Luke Albrecht
    General Counsel, Secretary
  • Steven Closter
    Chief Commercial Officer
  • Anjali Ganguli
    Chief Business Officer
  • Catherine Madigan
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.